Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Asclepius Meditec is a private Shanghai-based medical device company focused on hydrogen-oxygen inhalation systems for respiratory care and related adjunctive therapeutic use. The company is best known for its Class III medical-grade hydrogen-oxygen nebulizer/inhaler platform, which generates a fixed hydrogen-oxygen gas mixture through water electrolysis for hospital and home-care settings. It positions its products for respiratory and critical-care applications, and highlights clinical research activity in areas including COVID-19, COPD, and other pulmonary disorders. The business appears to be commercial-stage in China, with multiple NMPA medical device registrations and ongoing international expansion efforts. Asclepius Meditec operates more like a medtech/device company than a traditional biotech drug developer, with value centered on proprietary hardware, regulatory clearances, and clinical evidence generation around hydrogen-oxygen therapy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Asclepius Metidec.